Overview

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborators:
Eli Lilly and Company
Kom Op Tegen Kanker
Teva Pharma
Treatments:
abemaciclib
bicalutamide